Who Are the Real High-Risk Patients with Pathological T2N0M0 Non-Small-cell Lung Cancer That Can Benefit from Adjuvant Chemotherapy?
ESMO OPEN(2022)
关键词
non-small cell lung cancer,T2N0M0,adjuvant chemotherapy,survival
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要